NCT06774807

Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)

Antagonist of the Glucagon-like Peptide 2 (GLP-2) Receptor

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Copenhagen · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

This project will describe the role of physiological levels of GLP-2 in regulating the blood flow to the intestines and the effect of the antagonist GLP-2(3-33) in blocking these effects of GLP-2.

Detailed description

Ten healthy participants will meet fasting and attend four randomized experimental days of MRI-scans of the abdomen. Each day will include subcutaneous injections of GLP-2 or saline and intravenous infusion of either the GLP-2 (3-33) antagonist or saline. The infusion start at timepoint -20, while the subcutaneous injection is given to timepoint 0 and the participant will lay in the scanner in one hour after injection. Eight MR-scans are done repeatedly to measure the blood flow in larger abdominal vessels and four blood samples are taken during the experimental day for analysis of GLP-2(1-33), GLP-2(3-33) and bone markers.

Conditions

• Healthy

Interventions

Type	Name	Description
OTHER	Saline infusion	Saline/NaCl (9mg/ml) intravenous infusion
OTHER	Saline injection	Saline/NaCl (9mg/ml) subcutaneous injection
OTHER	1nmol antagonist infusion	GLP-2 (1-33)/GLP-2(3-33) 1 nmol/kg/min
OTHER	4 nmol antagonist infusion	GLP-2 (1-33)/GLP-2 (3-33) 4 nmol/kg/min
OTHER	Agonist injection	GLP-2(1-33) subcutaneous injection

Timeline

• Start date: 2024-05-01
• Primary completion: 2024-09-01
• Completion: 2024-09-07
• First posted: 2025-01-14
• Last updated: 2025-05-02

Locations

1 site across 1 country: Denmark